278 related articles for article (PubMed ID: 20843937)
21. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
23. Psychosocial interventions for men with prostate cancer.
Parahoo K; McDonough S; McCaughan E; Noyes J; Semple C; Halstead EJ; Neuberger MM; Dahm P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008529. PubMed ID: 24368598
[TBL] [Abstract][Full Text] [Related]
24. Shared decision-making for prostate cancer screening and treatment: a systematic review of randomised controlled trials.
Martínez-González NA; Plate A; Senn O; Markun S; Rosemann T; Neuner-Jehle S
Swiss Med Wkly; 2018; 148():w14584. PubMed ID: 29473938
[TBL] [Abstract][Full Text] [Related]
25. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
26. [Is the mass screening for prostate cancer justifiable?].
Döbrossy L; Kovács A; Budai A; Cornides A
Orv Hetil; 2007 Jul; 148(26):1213-6. PubMed ID: 17588854
[TBL] [Abstract][Full Text] [Related]
27. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study.
Weinmann S; Richert-Boe KE; Van Den Eeden SK; Enger SM; Rybicki BA; Shapiro JA; Weiss NS
Epidemiology; 2005 May; 16(3):367-76. PubMed ID: 15824554
[TBL] [Abstract][Full Text] [Related]
28. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
Nicholson A; Mahon J; Boland A; Beale S; Dwan K; Fleeman N; Hockenhull J; Dundar Y
Health Technol Assess; 2015 Oct; 19(87):i-xxxi, 1-191. PubMed ID: 26507078
[TBL] [Abstract][Full Text] [Related]
29. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.
Ilic D; Evans SM; Allan CA; Jung JH; Murphy D; Frydenberg M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009625. PubMed ID: 28895658
[TBL] [Abstract][Full Text] [Related]
30. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
Chou R; Croswell JM; Dana T; Bougatsos C; Blazina I; Fu R; Gleitsmann K; Koenig HC; Lam C; Maltz A; Rugge JB; Lin K
Ann Intern Med; 2011 Dec; 155(11):762-71. PubMed ID: 21984740
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
33. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
[TBL] [Abstract][Full Text] [Related]
34. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
Halpern JA; Oromendia C; Shoag JE; Mittal S; Cosiano MF; Ballman KV; Vickers AJ; Hu JC
J Urol; 2018 Apr; 199(4):947-953. PubMed ID: 29061540
[TBL] [Abstract][Full Text] [Related]
35. Mortality results from a randomized prostate-cancer screening trial.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Gelmann EP; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Clapp JD; Rathmell JM; Riley TL; Hayes RB; Kramer BS; Izmirlian G; Miller AB; Pinsky PF; Prorok PC; Gohagan JK; Berg CD;
N Engl J Med; 2009 Mar; 360(13):1310-9. PubMed ID: 19297565
[TBL] [Abstract][Full Text] [Related]
36. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
[TBL] [Abstract][Full Text] [Related]
37. Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.
Ito K; Oki R; Sekine Y; Arai S; Miyazawa Y; Shibata Y; Suzuki K; Kurosawa I
Int J Urol; 2019 Oct; 26(10):956-970. PubMed ID: 31183923
[TBL] [Abstract][Full Text] [Related]
38. Randomised prostate cancer screening trial: 20 year follow-up.
Sandblom G; Varenhorst E; Rosell J; Löfman O; Carlsson P
BMJ; 2011 Mar; 342():d1539. PubMed ID: 21454449
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
